Micafungin for the treatment of invasive aspergillosis

摘要: Invasive aspergillosis is a major cause of morbidity and mortality in immunocompromised patients, particularly those with neutropenia undergoing bone marrow or stem cell transplants. Micafungin an echinocandin antifungal drug activity against all Candida spp. Currently, micafungin indicated for treatment invasive candidiasis, oesophageal candidiasis prophylaxis infection patients allogeneic haematopoietic transplantation who are expected to have neutropenia. demonstrates in vitro in vivo Aspergillus It currently not licensed treat infections the UK USA. This review summarises current evidence base surrounding clinical use consider potential role these patients. There no randomised studies comparing standard therapy. Prospective non-randomised studies, predominantly performed Japan, involving 492 455 febrile chemotherapy-induced suggest that may be as effective comparator agents. Other limited case reports. Further experience form controlled trials required establish exact context available broad-spectrum